HAVAH Therapeutics
HAVAH Therapeutics develops T+Ai, a therapy aimed at reducing breast cancer risk and improving wellbeing in women. It achieves this through targeted modulation of hormonal balance in the breast using a proprietary combination therapy. The company is a clinical-stage pharmaceutical company focusing on breast cancer prevention and hormonal therapies. Core technology includes hormone regulation strategies and supporting safety and pharmacokinetic data from early studies. The market focus is women at risk worldwide seeking preventive options with manageable side effects and improved quality of life.
HAVAH Therapeutics
HAVAH Therapeutics develops T+Ai, a therapy aimed at reducing breast cancer risk and improving wellbeing in women. It achieves this through targeted modulation of hormonal balance in the breast using a proprietary combination therapy. The company is a clinical-stage pharmaceutical company focusing on breast cancer prevention and hormonal therapies. Core technology includes hormone regulation strategies and supporting safety and pharmacokinetic data from early studies. The market focus is women at risk worldwide seeking preventive options with manageable side effects and improved quality of life.